Microbiome Targeted Drugs Articles & Analysis
24 news found
LB-P8, a novel drug being developed by LISCure Biosciences, Inc. (LISCure) as a treatment for Primary Sclerosing Cholangitis (PSC), has been designated as an orphan drug by the US FDA. On December 1, 2022, the US FDA notified LISCure of the orphan drug designation of LB-P8, LISCure's microbiome novel drug, as treatment of PSC. LB-P8 is, to the best of company's knowledge, the first drug to be ...
About SER-109 SER-109 is an oral microbiome therapeutic candidate consisting of a consortium of highly purified Firmicutes spores, which normally live in a healthy microbiome. ...
Food and Drug Administration (FDA) in mid-2022, positioning SER-109 up to potentially become the first ever FDA-approved microbiome-based therapeutic for treating recurrent C. difficile infections with a potential product launch in the first half of 2023. ...
--(BUSINESS WIRE)--Mar. 18, 2022-- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, will present preclinical findings tomorrow at the European Bone Marrow Transplantation (EBMT) Annual Meeting that suggest SER-155 works by targeting the host immune response, potentially allowing patients undergoing hematopoietic stem cell ...
Seres expects to finalize a Biologics License Application (BLA) submission for SER-109 with the U.S. Food and Drug Administration (FDA) in mid-2022. “We are eager to showcase new data that further validate the potential of our investigational microbiome therapeutic, SER-109, at the world’s largest gathering of physicians and researchers in the ...
SER-109 was well tolerated, with a side effect profile comparable to placebo and no serious drug-related adverse events observed. SER-155 Phase 1b clinical study activities:In December 2021, Seres announced the enrollment of the first patient in the Company’s Phase 1b clinical study of SER-155 designed to evaluate safety, microbiome alterations, and the ...
The Microbiome Therapeutics Innovation Group (MTIG) today announced the addition of Bio-Me to its coalition of companies leading the research and development of FDA-approved microbiome therapeutic drugs and microbiome-based products. Bio-Me offers a wide range of proprietary solutions to facilitate the gut microbiome analysis process for academia and pharma researchers and is setting the ...
ByBio-Me
Our CEO Claudio Hidalgo will be attending the Pharmabiotics Event 2022 taking place on April 20th-21st at Lyon. The Pharmabiotics Conference brings together players from academia and industry and it is an incredible opportunity to meet stakeholders and discuss the further innovation in microbiome-based drug products and regulatory affairs. Reach out to us if you want to meet during the ...
Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer (DFU), other chronic ...
Dr. Ryan Gordon has joined the Stem Pharm team as Sr. V.P. of Business Development and Commercialization. Gordon brings to Stem Pharm over 20 years of business, R&D, and operational experience in developing and commercializing innovative biopharmaceutical technologies to revolutionize disease treatment and improve patient outcomes. He has been a valued leader at large companies (3M) and ...
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 6thMicrobiome Movement – Drug Development Summit Europe 2022 in London during January 25th-27th, 2022. The presentation has been included in stream A titled “Understanding mechanisms of action & preclinical development” the 26th at 13.45. Microbiota Adaptation ...
EnteroBiotix, a biopharmaceutical company developing novel highly-diverse microbial therapeutics that enhance the gut microbiome, today announced the mechanical completion of a new purpose built world-class facility at Strathclyde Business Park, Glasgow, for manufacturing and quality control of its high-diversity microbial therapeutics, and an expansion of its corporate offices to support an ...
EnteroBiotix, a biopharmaceutical company developing novel high-diversity microbial therapeutics that enhance the gut microbiome and target multiple indications, today announced the final closing of its oversubscribed USD $21.5 million (UK £15.5m) Series A financing. The proceeds will be used to further advance the company’s ...
Isaksen will first be presenting how we support companies in their development of microbiome modulating drugs with our PMP™ technology for targeted microbiome analysis. ...
ByBio-Me
” SFA plans to expand the evaluation of one of its six microbiome-derived drugs, SFA002, in this new trial. This 30-subject open-label clinical trial in patients with mild-to-moderate psoriasis will enroll 30 subjects into two cohorts with 15 subjects each. ...
We are happy to announce that Fabio Grassi (MV BioTherapeutics founder) has been invited to contribute to the 5th Microbiome Movement – Drug Development Summit Europe 2021 being held virtually during January 27th-29th, 2021. The presentation has been included in the morning stream titled “Introducing the Era of Engineered Microbes” the 29th at 11.35. Leveraging Gut Microbiota ...
Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keynote, titled ...
The $2 million in Phase II grant funding will support preclinical efforts to select and develop a bacteria-targeting, non-antibiotic lead candidate to improve cancer chemotherapy outcomes. Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI ...
LISCure Biosciences, a biotech company that researches and develops bacteria-mediated immunotherapy, has succeeded in attracting 5 million USD of seed funding investment. NHN Investment, Shinhan Investment, and KB Securities have participated in the financing, and LISCure is expected to strengthen its research and development capabilities of key technologies with the funds. ...
Long-term objectives of the planned work include the development of a therapeutic adjunct to prevent adverse gastrointestinal events associated with essential drugs and the development of a microbiome-targeted drug to treat inflammatory bowel disease. Symberix is developing first-in-class therapies that target ...